437 related articles for article (PubMed ID: 31694706)
21. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.
Idorn M; Køllgaard T; Kongsted P; Sengeløv L; Thor Straten P
Cancer Immunol Immunother; 2014 Nov; 63(11):1177-87. PubMed ID: 25085000
[TBL] [Abstract][Full Text] [Related]
22. Myeloid-derived suppressor cell function is reduced by Withaferin A, a potent and abundant component of Withania somnifera root extract.
Sinha P; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2013 Nov; 62(11):1663-73. PubMed ID: 23982485
[TBL] [Abstract][Full Text] [Related]
23. AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells.
Trillo-Tinoco J; Sierra RA; Mohamed E; Cao Y; de Mingo-Pulido Á; Gilvary DL; Anadon CM; Costich TL; Wei S; Flores ER; Ruffell B; Conejo-Garcia JR; Rodriguez PC
Cancer Res; 2019 Oct; 79(19):5034-5047. PubMed ID: 31409640
[TBL] [Abstract][Full Text] [Related]
24. Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer.
de Goeje PL; Bezemer K; Heuvers ME; Dingemans AC; Groen HJ; Smit EF; Hoogsteden HC; Hendriks RW; Aerts JG; Hegmans JP
Oncoimmunology; 2015 Jul; 4(7):e1014242. PubMed ID: 26140237
[TBL] [Abstract][Full Text] [Related]
25. High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege.
Ager CR; Boda A; Rajapakshe K; Lea ST; Di Francesco ME; Jayaprakash P; Slay RB; Morrow B; Prasad R; Dean MA; Duffy CR; Coarfa C; Jones P; Curran MA
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34341132
[TBL] [Abstract][Full Text] [Related]
26. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function.
Nam S; Kang K; Cha JS; Kim JW; Lee HG; Kim Y; Yang Y; Lee MS; Lim JS
J Leukoc Biol; 2016 Dec; 100(6):1273-1284. PubMed ID: 27601624
[TBL] [Abstract][Full Text] [Related]
27. Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model.
Du Four S; Maenhout SK; De Pierre K; Renmans D; Niclou SP; Thielemans K; Neyns B; Aerts JL
Oncoimmunology; 2015 Apr; 4(4):e998107. PubMed ID: 26137411
[TBL] [Abstract][Full Text] [Related]
28. Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer.
Ma P; Beatty PL; McKolanis J; Brand R; Schoen RE; Finn OJ
Front Immunol; 2019; 10():1401. PubMed ID: 31275327
[TBL] [Abstract][Full Text] [Related]
29. Engineered Bacterial Biomimetic Vesicles Reprogram Tumor-Associated Macrophages and Remodel Tumor Microenvironment to Promote Innate and Adaptive Antitumor Immune Responses.
Zheng P; He J; Fu Y; Yang Y; Li S; Duan B; Yang Y; Hu Y; Yang Z; Wang M; Liu Q; Zheng X; Hua L; Li W; Li D; Ding Y; Yang X; Bai H; Long Q; Huang W; Ma Y
ACS Nano; 2024 Mar; 18(9):6863-6886. PubMed ID: 38386537
[TBL] [Abstract][Full Text] [Related]
30. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
[TBL] [Abstract][Full Text] [Related]
31. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism.
Waight JD; Hu Q; Miller A; Liu S; Abrams SI
PLoS One; 2011; 6(11):e27690. PubMed ID: 22110722
[TBL] [Abstract][Full Text] [Related]
32. Myeloid derived suppressor cells in tumor microenvironment: Interaction with innate lymphoid cells.
Tumino N; Fiore PF; Pelosi A; Moretta L; Vacca P
Semin Immunol; 2022 Nov; 61-64():101668. PubMed ID: 36370673
[TBL] [Abstract][Full Text] [Related]
33. The Tautomerase Activity of Tumor Exosomal MIF Promotes Pancreatic Cancer Progression by Modulating MDSC Differentiation.
Jia X; Xi J; Tian B; Zhang Y; Wang Z; Wang F; Li Z; Long J; Wang J; Fan GH; Li Q
Cancer Immunol Res; 2024 Jan; 12(1):72-90. PubMed ID: 37956411
[TBL] [Abstract][Full Text] [Related]
34. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.
Chen HM; Ma G; Gildener-Leapman N; Eisenstein S; Coakley BA; Ozao J; Mandeli J; Divino C; Schwartz M; Sung M; Ferris R; Kao J; Wang LH; Pan PY; Ko EC; Chen SH
Clin Cancer Res; 2015 Sep; 21(18):4073-4085. PubMed ID: 25922428
[TBL] [Abstract][Full Text] [Related]
35. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients.
Li J; Srivastava RM; Ettyreddy A; Ferris RL
J Immunother Cancer; 2015; 3():54. PubMed ID: 26579227
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.
Porembka MR; Mitchem JB; Belt BA; Hsieh CS; Lee HM; Herndon J; Gillanders WE; Linehan DC; Goedegebuure P
Cancer Immunol Immunother; 2012 Sep; 61(9):1373-85. PubMed ID: 22215137
[TBL] [Abstract][Full Text] [Related]
37. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.
Li H; Han Y; Guo Q; Zhang M; Cao X
J Immunol; 2009 Jan; 182(1):240-9. PubMed ID: 19109155
[TBL] [Abstract][Full Text] [Related]
38. Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma.
Duewell P; Beller E; Kirchleitner SV; Adunka T; Bourhis H; Siveke J; Mayr D; Kobold S; Endres S; Schnurr M
Oncoimmunology; 2015 Oct; 4(10):e1029698. PubMed ID: 26504669
[TBL] [Abstract][Full Text] [Related]
39. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
Parker KH; Beury DW; Ostrand-Rosenberg S
Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
[TBL] [Abstract][Full Text] [Related]
40. Dabrafenib Alters MDSC Differentiation and Function by Activation of GCN2.
Ciudad MT; Quevedo R; Lamorte S; Jin R; Nzirorera N; Koritzinsky M; McGaha TL
Cancer Res Commun; 2024 Mar; 4(3):765-784. PubMed ID: 38421883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
